This isn’t about managing the AIDS pandemic. It’s about ending it — and letting a new generation grow and thrive free of its ...

The Global Fund has secured access to lenacapavir, a groundbreaking HIV prevention drug, for low and middle-income countries, ...

The fact that lenacapavir will soon be available to patients is a testament to the strength of America's biopharmaceutical ...

Gilead will supply lenacapavir to Global Fund countries for HIV prevention, but questions remain amid PEPFAR cuts and funding ...

The drugmaker will provide, at no profit, doses to treat up to 2 million people in resource-limited countries. Meanwhile, ...

The Minister’s address was particularly notable for the announcement of a planned rollout of lenacapavir, a biannual ...

Lenacapavir offers twice-yearly HIV prevention with near-complete protection in clinical trials. Clinical trials show ...

Only 17,000 Ugandans to benefit from $1.1m Global Fund support as officials warn of high demand for long-acting prevention ...

Gilead announced a deal to get its groundbreaking HIV prevention drug to lower income countries. Notably, the deal does not ...

Lower-income countries will gain access to a "game-changing" HIV prevention drug with a new deal signed between US ...

Gilead Sciences and the Global Fund to Fight AIDS, Tuberculosis and Malaria said on Wednesday they had finalized plans to supply a long-acting HIV prevention drug to low-income countries, despite the ...

Gilead Sciences (GILD) stock in focus as the company joins The Global Fund to expand access to lenacapavir, an HIV PrEP ...